Lewis & Clark
SlowingSt. Louis, MOBiotechnology, HealthcareLast fund filed May 2025
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Lewis & Clark AgriFood Fund III | May 2025 | Indefinite | $42M | 23 |
| Lewis & Clark RBIC Fund III | December 2023 | $150M | $70M | 8 |
| Lewis & Clark Ventures II | 2021 | Indefinite | $55M | 37 |
| Lewis & Clark RBIC Fund II | December 2019 | $125M | $76M | 10 |
| Lewis & Clark AgriFood Fund II | June 2019 | $169M | $169M | 77 |
| Lewis & Clark Plant Sciences Fund I | August 2016 | $45M | $20M | 1 |
| Lewis & Clark Ventures I Parallel Fund | November 2015 | $25M | $25M | 1 |
| Lewis & Clark Ventures I | July 2015 | Indefinite | $71M | 33 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David Taiclet | Slowing | None listed | 1 | 1 |
| Brian HopcraftNot on the current fund | Quiet | Enterprise software, Biotech & pharma, Climate & energy | 8 | 0 |
| Lawrence Page | Quiet | Biotech & pharma, Food & agriculture, Manufacturing & industrials | 15 | 0 |
| Thomas Hillman | Quiet | Medical devices | 3 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Lewis & Clark’s own portfolio companies, based on 10 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Lewis & Clark’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Cultivation Capital Life Sciences | 3 | Adarza BioSystems, Euphrates Vascular, Pulse Therapeutics |
| Arthur Ventures | 1 | Catalyze |
| Baird Venture Partners | 1 | Catalyze |
| HealthX Ventures | 1 | Catalyze |
| Kleiner Perkins | 1 | Alphabet |
| Michigan Elab Capital Partners | 1 | Blue Medora |
| Pandemic Innovation | 1 | Catalyze |
| Rivervest | 1 | Adarza BioSystems |
| U.S Venture Partners | 1 | Territory Foods |
A shared board seat: a company where filings name a Lewis & Clark partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.